ESC Premium Access

Prognosis and cost-effectiveness of cardiac rehabilitation

Event: ESC CONGRESS 2016
Topic: Cardiovascular rehabilitation: interventions and outcomes
Session type: Moderated Posters
Date: 29 August 2016
Time: 10:05 - 10:55

Congress Session

7 presentations in this session

Mortality benefit of cardiac rehabilitation after myocardial infarction in the modern era

Speaker: Doctor J. Klein (Jerusalem, IL)

Increase in 6-minute walk distance during hospitalization predicts the readmission due to decompensated heart failure in patients with chronic heart failure

Speaker: Associate Professor M. Tabata (Tokyo, JP)

Participation in exercise-based cardiac rehabilitation is associated with improved levels of risk factors in myocardial infarction survivors

Speaker: Mrs I. Sjolin (Lund, SE)

Determinants and outcome of drop-out in outpatient cardiac rehabilitation

Speaker: Doctor S. Pardaens (Aalst, BE)

The benefits of cardiac rehabilitation in coronary artery disease: does the weight matter?

Speaker: Doctor M. Braga (Porto, PT)

Peak oxygen uptake during exercise testing and long-term cardiovascular events in patients with coronary artery disease undergoing cardiac rehabilitation: a population-based study

Speaker: Doctor J. Medina-Inojosa (Rochester, US)

Cost effectiveness analysis of a cardiac rehabilitation program after an acute coronary syndrome

Speaker: Mr R. Andion Ogando (Valladolid, ES)

7 speakers from this session

Doctor Jacob Klein

Shaare Zedek Medical Center, Jerusalem (Israel)
0 follower

Associate Professor Minoru Tabata

Tokyo Professional University of Health Sciences, Tokyo (Japan)
0 follower

Mrs Ingela Sjolin

Lund University, Lund (Sweden)
0 follower

Doctor Sofie Pardaens

Olv Hospital Aalst, Aalst (Belgium)
1 presentation
0 follower

Doctor Marta Braga

Sao Joao Hospital, Porto (Portugal)
2 presentations
0 follower

Doctor Jose R Medina-Inojosa

Mayo Clinic, Rochester (United States of America)
0 follower

Mr Ramon Andion Ogando

0 follower

This platform is supported by

logo Novo Nordisk